This trial is active, not recruiting.

Condition hematological malignancies
Treatments full intensity, double umbilical cord, stem cell transplant, flu/bu4 conditioning regimen, total lymphoid irradiation (tli), graft versus host disease prevention (gvhd prophylaxis)
Phase phase 2
Sponsor University of Michigan Cancer Center
Collaborator Otsuka Pharmaceutical Development & Commercialization, Inc.
Start date December 2008
End date January 2014
Trial size 30 participants
Trial identifier NCT00763490, HUM00017515, umcc 2007.137


This pilot research study is to investigate the safety and effectiveness of stem cell transplantation to treat blood-related (hematopoietic) cancers, using stem cells collected from two different, umbilical cord blood donors. Subjects in this study are receiving a stem cell transplant because other treatments have failed or their disease is unlikely to respond to other treatment options.

Blood-related cancers can be treated and sometimes cured with very high doses of chemotherapy and radiation therapy, given to kill the cancer cells; however, these treatments can prove unsuccessful and can harm normal cells in the bone marrow or a patient's disease may be unlikely to respond to these treatment options.

Hematopoietic stem cells transplantation (HSCT) is a potential cure, but opportunities to perform HSCT are limited by donor availability. Only 20-30% of patients may have matched family donors. In some cases, a mismatched family donor may be suitable. For patients needing a transplant who do not have a suitably matched family donor, blood stem cells from matched unrelated donors can be used. The length of time required to identify a matched unrelated donor presents another obstacle for patients waiting to receive an HSCT.

Blood stem cells are found in umbilical cord blood (UCB), which is blood left over in the placenta (afterbirth) after a baby is born. Usually this blood is discarded with the placenta, but over the past 15 years, we have learned how to collect and freeze cord blood cells to be used for transplants at a later time. A cord blood unit is the cord blood cells collected and stored from a single placenta. More than 6,500 umbilical cord blood stem cell transplants have been done worldwide, mostly in children with leukemia. One important factor affecting the success of a cord blood transplant is the cell dose (number of stem cells in the cord blood unit / recipient's weight). Patients who receive a high cell dose (> 2.5 x 107 cells/kilogram) have better marrow recovery and a higher rate of survival than those who receive a lower cell dose.

In an attempt to make UCB transplantation possible for bigger children, adolescents and adults, researchers have tried giving two cord blood units on the same day for their transplant, one after the other. The data from more than 150 "double cord blood" transplants in adults suggest that the "double cord blood" transplants may allow bone marrow recovery and survival in patients who do not have a single cord blood unit with enough cells for successful transplantation.

This is a pilot study to research the safety and effectiveness of using two UCB units in adult and pediatric UCB transplantation when combined with a conditioning regimen called Flu/Bu4/TLI (consisting of fludarabine, busulfan and total lymphoid irradiation).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
full intensity, double umbilical cord, stem cell transplant
stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
flu/bu4 conditioning regimen
Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2 Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2
total lymphoid irradiation (tli)
one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
graft versus host disease prevention (gvhd prophylaxis)
Co-enrollment on an active U-M study for GVHD prophylaxis is allowed, else a combination of tacrolimus and Mycophenolate Mofetil (MMF). Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and GFR < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated. MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued.

Primary Outcomes

One-year survival rate after transplant
time frame: 1 year

Secondary Outcomes

Overall and disease free survival at two years and five years
time frame: 5 years
Incidence of neutrophil and platelet engraftment
time frame: 1 year
Incidence of acute and chronic graft-vs-host disease(GvHD) and relapse
time frame: 1 year
Correlation between regulatory T cell numbers post-transplant with GVHD outcomes observed during the trial
time frame: 1 year

Eligibility Criteria

Male or female participants up to 65 years old.

Inclusion Criteria: - The candidate must have an incurable hematological malignancy or non-malignant hematological disorder and be eligible for transplant by the UM program. - The candidate must have a life expectancy of less than one year without transplantation. - The candidate must have two partially HLA-matched UCB (cord blood) units.Units must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing) loci. Units must be HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with each other (using same resolution of molecular typing as indicated above). - The candidate must have access to two appropriately HLA-matched units that are available such that one unit delivers a pre-cryopreserved nucleated cell dose of at least 2.5 x 107 per kilogram and the second unit at least 2.0 x 107 per kilogram. Exclusion Criteria: - The candidate is an adult or pediatric patient who has a suitable related or unrelated donor available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation. - The candidate has a Karnofsky (Adult) or Lansky (Pediatrics) performance status of < 70% at the time of admission for HSCT. - The candidate is a patient with evidence of HIV infection. - The candidate is a patient with active bacterial, fungal or viral infection not responding to treatment. Non-response to treatment is determined by body temperature, blood culture results, and radiographic findings as applicable. - The candidate is pregnant. - The candidate has any medical comorbidities/conditions that, in the opinion of the transplant team, would keep the patient from complying with the needs of the protocol and/or would markedly increase the morbidity and mortality from the procedure. - The candidate has any conditions, in the opinion of the transplant team, such as substance abuse, or severe personality disorder that would keep the patient from complying with the needs of the protocol and would markedly increase the morbidity and mortality from the procedure.

Additional Information

Official title Trial Of Double Umbilical Cord Blood Transplantation
Principal investigator Daniel M Couriel, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by University of Michigan Cancer Center.